Overview

• Meta-analysis indicates high-dose psilocybin's effect on depression is similar to escitalopram.
• Researchers highlight lower placebo responses in psychedelic trials compared to antidepressant trials.
• Study calls for improved blinding methods to accurately assess psychedelic efficacy.
• Findings suggest psychedelics may offer a new avenue for depression treatment, but long-term effects remain unclear.
• No significant increase in severe adverse events was associated with psilocybin treatments.